Vaccination of Lewis rats with temperature-sensitive mutants of Mycoplasma pulmonis: adoptive transfer of immunity by spleen cells but not by sera

Lai, Wayne C.; Bennett, Michael V. L.; Lu, Y S; Pakes, S. P.

doi:10.1128/iai.59.1.346-350.1991

Cited by 14 publications

(4 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…On the other hand, the role of cellular immune responses in mycoplasmosis appears to be controversial. The passive transfer of M. pulmonis-immune splenic lymphocytes protects against infection in rats (13). However, rats and mice that are deficient in T cells also develop less severe respiratory disease than do immunocompetent animals after infection with M. pulmonis (4).…”

Section: Introductionmentioning

confidence: 99%

Production of a T‐Cell Clone Which Reacts with Membrane Proteins of Acholeplasma laidlawii

Kuwano

Ono

Akashi

et al. 1997

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Production of a T‐Cell Clone Which Reacts with Membrane Proteins of Acholeplasma laidlawii

Kuwano

Ono

Akashi

et al. 1997

Microbiology and Immunology

View full text Add to dashboard Cite

show abstract

“…Studies have shown that the depletion of CD8 + T cells exacerbated pneumonia in a murine model of mycoplasma infection. [10][11][12] Compared to vaccines without adjuvant, inactivated vaccines with an adjuvant that was capable of inducing CD8 + T cell responses reduced lung lesion size in pigs with M. hyopneumoniae infection. [13] Live attenuated wholecell bacteria were used as attenuated mycoplasma vaccines, which induced activation of lung CD8 + T cells in vivo.…”

mentioning

confidence: 99%

Long‐Residence Pneumonia Vaccine Developed Using PEG‐Grafted Hybrid Nanovesicles from Cell Membrane Fusion of Mycoplasma and IFN‐γ‐Primed Macrophages

Zhang

Wang

Xie

et al. 2021

Small

View full text Add to dashboard Cite

and no commercial vaccines are currently available for humans. [1,2] Great progress has been achieved in the development of mycoplasma vaccines. Inactivated vaccines have been developed and tested in clinical trials, with an overall efficacy of approximately 40% against Mycoplasma pneumoniae infection in humans. [3] Live attenuated or inactivated vaccines have been widely used to control Mycoplasma hyopneumoniae infection in pigs. [4][5][6][7][8] Compared to live attenuated vaccines, inactivated vaccines provide high safety with limited efficacy due to protein denaturation and degradation. [9] Therefore, it is highly desirable to develop safe and effective vaccines against mycoplasma infection.CD8 + T cell responses play a critical regulatory role in protection against mycoplasma infection-related respiratory diseases. Studies have shown that the depletion of CD8 + T cells exacerbated pneumonia in a murine model of mycoplasma infection. [10][11][12] Compared to vaccines without adjuvant, inactivated vaccines with an adjuvant that was capable of inducing CD8 + T cell responses reduced lung lesion size in pigs with M. hyopneumoniae infection. [13] Live attenuated wholecell bacteria were used as attenuated mycoplasma vaccines, which induced activation of lung CD8 + T cells in vivo. [14,15] CD8 + T cell responses play a critical regulatory role in protection against mycoplasma infection-related respiratory diseases. Nanovesicles derived from cell membranes have been shown to induce CD8 + T cell responses. Moreover, the short residence time of mycoplasma membrane-related vaccines in local lymph nodes limits the efficacy of current mycoplasma vaccines. Here, a long-residence pneumonia vaccine is developed using nanovesicles prepared by cell membrane fusion of Mycoplasma hyopneumoniae and interferon-γ (IFN-γ )-primed macrophages, which are grafted with polyethylene glycol to increase residence time in the lymph nodes. Upregulation of intercellular adhesion molecule-1 (ICAM-1) on the membrane of IFN-γ-primed macrophages increases the targeting of the hybrid nanovesicle vaccine to the local lymph nodes, with increased CD8 + T cell activation. A mechanistic study reveals that CD8 + T cell activation is achieved via a pathway involving upregulation of C-C motif chemokine ligand 2/3 expression by E26 transformation-specific sequences, followed by increased immune-stimulatory activity of dendritic cells. In vivo, prophylactic testing reveals that the hybrid nanovesicle vaccine triggers a long-term immune response, as evidenced by a memory CD8 + T cell response against mycoplasma infection. The current study provides a new design strategy for mycoplasma vaccines that involves a hybrid method using biological sources and artificial modification.

show abstract

“…Currently, animal colonies are monitored by the detection of specific antibody in serum that is elicited during infection with M. pulmonis, but it has been shown that animals can be infected and yet display seronegativity up to 4 weeks postinfection (5). In spite of these diagnostic antibody responses, data from Lai et al (25) have indicated that the principal protective feature of immunity to respiratory lesions caused by M. pulmonis may be cell-mediated immune responses. The same report also noted that while different strains of rodents have different susceptibilities to M. pulmonis, other studies suggest that preexisting antibody can be protective in mice but not in rats (25).…”

mentioning

confidence: 99%

“…In spite of these diagnostic antibody responses, data from Lai et al (25) have indicated that the principal protective feature of immunity to respiratory lesions caused by M. pulmonis may be cell-mediated immune responses. The same report also noted that while different strains of rodents have different susceptibilities to M. pulmonis, other studies suggest that preexisting antibody can be protective in mice but not in rats (25). Recognizing that the mucosal surfaces are the site of initial colonization and infection, it could be hypothesized that secretory immune responses are capable of interfering with the pathogenesis of this microorganism.…”

mentioning

confidence: 99%

Secretory immune responses to Mycoplasma pulmonis

Steffen

Ebersole

1992

Infect Immun

View full text Add to dashboard Cite

Formalinized Mycoplasma pulmonis, along with aluminum hydroxide as an adjuvant, was used to subcutaneously immunize rats in the vicinity of the salivary gland to examine the characteristics of the secretory immune response to this pathogen. The induction of specific antibody to this microorganism was detected in serum and the exocrine fluids, namely, saliva and lung lavage fluid. Both immunoglobulin G (IgG) and IgA isotype antibodies were detected in each of these fluids after primary and secondary local immunizations. Serum responses from immunized animals were significantly greater than in the control group, but a dose response was not observed in either IgG or IgA antibody at the dosages selected for immunization. Salivary IgG antibody responses peaked early after both the primary and secondary immunizations, exhibiting a clear dose response. Salivary IgA in immunized groups was significantly greater than that in the control group but displayed little dose-dependent kinetics, and, at the termination of the experinent, this response had not yet peaked. Lung lavage IgG and IgA were minimal after the primary immunization when the antibody was normalized to total protein but displayed dose-dependent kinetics after a secondary challenge. IgG peaked immediately after a secondary challenge, while IgA peak responses were observed only after 20 days. A positive correlation was noted between the serum, saliva, and lung lavage fluid IgGs after both primary and secondary immunizations and only after a secondary challenge for IgA. In this study we were able to elicit a secretory immune response, consisting of both IgG and IgA, which exhibited a dose-dependent characteristic in lung lavage fluid to this immunogen. Additionally, a positive correlation of antibody levels between saliva and lung lavage fluid suggests that saliva could be used as an indicator for monitoring specific antibody to M. pulmonis in lung lavage secretions without requiring invasive, deleterious procedures.

show abstract

Vaccination of Lewis rats with temperature-sensitive mutants of Mycoplasma pulmonis: adoptive transfer of immunity by spleen cells but not by sera

Abstract: Temperature-sensitive mutant vaccines protect rats against Mycoplasma pulmonis infection. The role of the humoral or cellular immune response in resistance to mycoplasma infection was investigated by adoptive-346

Cited by 14 publications

References 19 publications

Production of a T‐Cell Clone Which Reacts with Membrane Proteins of Acholeplasma laidlawii

Production of a T‐Cell Clone Which Reacts with Membrane Proteins of Acholeplasma laidlawii

Long‐Residence Pneumonia Vaccine Developed Using PEG‐Grafted Hybrid Nanovesicles from Cell Membrane Fusion of Mycoplasma and IFN‐γ‐Primed Macrophages

Secretory immune responses to Mycoplasma pulmonis

Contact Info

Product

Resources

About